Treatment for MPS I - A Patient's Perspective

Erika Thiel
Published Online: February 16, 2017

Erika Thiel of GeneSpotlight talks about her rare disease - Mucopolysaccharidosis (MPS) 1 - and  the limitations of the currently approved enzyme replacement therapy [Aldurazyme (laronidase)].

Latest Articles
Doctors at Stanford University have developed an experimental therapy that aims to cure epidermolysis bullosa.
Ava, an 11-year-old girl with Type 1 Usher Syndrome, hopes to win the attention of Usher by inspiring others to dance and share her story. Usher syndrome is a rare inherited condition that causes hearing and vision loss in early adolescence.
The 2017 Global Genes’ Denim Dash, a 5K run, will occur on April 13 at the Newport Dunes Waterfront Resort & Marina, Newport Beach, CA. All proceeds from the run will go to Global Genes' RARE Patient Impact Grant.
Data from two Phase 3 cystic fibrosis study indicated Vertex’s new combination therapy (tezacaftor / ivacaftor) will be a winner.
$vacMongoViewPlus$ $vAR$